Research News

Ovarian Cancer Will Continue to be Sequenced After The Cancer Genome Atlas Ends

The Cancer Genome Atlas (TCGA), a massive U.S. effort to genetically profile 10,000 tumors, has officially come to an end…

Read on

Palliative Care Consultation Improves Symptoms in Gynecologic Cancer Patients

A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation…

Read on

FDA Approves Olaparib for Ovarian Cancer

(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly ADP-ribose polymerase) inhibitor class…

Read on

Under the Microscope: OCRF’s 2014 Research Progress Report

(12/14/14) | In 2014, with your generous support OCRF grantees made significant advances in the fight against ovarian cancer, including: Identified a biomarker that may predict treatment response Shed new light on ovarian cancer metastasis…

Read on

OCRF Research Shows Targeting microRNA May Benefit Some Ovarian Cancer Patients

(December 10, 2014) OCRF Ann Schreiber Mentored Investigator Award Grantee, Pradeep Chaluvally-Raghavan, Ph.D…

Read on

Population Screening for BRCA Mutations in Ashkenazi Jewish Women is Cost-Effective

Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing…

Read on

FDA Approves Genentech's Avastin Plus Chemotherapy to Treat Women With Platinum-Resistant Recurrent Ovarian Cancer

Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer…

Read on

Bevacizumab Plus Fosbretabulin Improves Progression-Free Survival in Ovarian Cancer Patients

The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at…

Read on

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial…

Read on

Diet May Influence Ovarian Cancer Survival

According to a new study published in the Journal of the National Cancer Institute, a good diet before diagnosis is linked with lower mortality among ovarian cancer survivors…

Read on

Use of Intensive Medical Services for Ovarian Cancer Patients at End of Life Increases Despite Rise in Use of Hospice

There have been widespread efforts to improve the quality of life of terminally ill patients…

Read on

Telomere Length and Mortality Following An Ovarian Cancer Diagnosis

Telomeres are essential for the maintenance of chromosomal integrity. Telomere shortening leads to genomic instability, which is hypothesized to play a role in cancer development and prognosis…

Read on